Zhejiang Jiuzhou Pharmaceutical Co., Ltd

SHSE:603456 Stock Report

Market Cap: CN¥12.3b

Zhejiang Jiuzhou Pharmaceutical Valuation

Is 603456 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 603456 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 603456 (CN¥13.69) is trading above our estimate of fair value (CN¥12.34)

Significantly Below Fair Value: 603456 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 603456?

Other financial metrics that can be useful for relative valuation.

603456 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA7.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does 603456's PE Ratio compare to its peers?

The above table shows the PE ratio for 603456 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average43.9x
300181 Zhejiang Jolly PharmaceuticalLTD
24.6x22.3%CN¥10.5b
605116 Aurisco PharmaceuticalLtd
32.6x24.0%CN¥10.6b
300049 Inner Mongolia Furui Medical Science
104x40.5%CN¥13.7b
002737 Sunflower Pharmaceutical GroupLtd
14.6xn/aCN¥14.1b
603456 Zhejiang Jiuzhou Pharmaceutical
12.4x16.4%CN¥12.3b

Price-To-Earnings vs Peers: 603456 is good value based on its Price-To-Earnings Ratio (12.4x) compared to the peer average (43.9x).


Price to Earnings Ratio vs Industry

How does 603456's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 603456 is good value based on its Price-To-Earnings Ratio (12.4x) compared to the CN Pharmaceuticals industry average (28.2x).


Price to Earnings Ratio vs Fair Ratio

What is 603456's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

603456 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.4x
Fair PE Ratio24.6x

Price-To-Earnings vs Fair Ratio: 603456 is good value based on its Price-To-Earnings Ratio (12.4x) compared to the estimated Fair Price-To-Earnings Ratio (24.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 603456 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥13.69
CN¥23.20
+69.5%
4.1%CN¥24.00CN¥21.60n/a4
Jul ’25CN¥13.70
CN¥23.20
+69.4%
4.1%CN¥24.00CN¥21.60n/a4
Jun ’25CN¥15.09
CN¥23.20
+53.8%
4.1%CN¥24.00CN¥21.60n/a4
May ’25CN¥16.12
CN¥23.20
+43.9%
4.1%CN¥24.00CN¥21.60n/a4
Apr ’25CN¥18.13
CN¥37.79
+108.5%
7.5%CN¥40.67CN¥33.10n/a4
Mar ’25CN¥20.46
CN¥37.79
+84.7%
7.5%CN¥40.67CN¥33.10n/a4
Feb ’25CN¥18.31
CN¥37.79
+106.4%
7.5%CN¥40.67CN¥33.10n/a4
Jan ’25CN¥24.21
CN¥37.79
+56.1%
7.5%CN¥40.67CN¥33.10n/a4
Dec ’24CN¥28.13
CN¥37.79
+34.3%
7.5%CN¥40.67CN¥33.10n/a4
Nov ’24CN¥28.53
CN¥37.04
+29.8%
7.6%CN¥40.67CN¥33.10n/a4
Oct ’24CN¥28.98
CN¥39.26
+35.5%
12.4%CN¥47.45CN¥35.20n/a4
Sep ’24CN¥26.75
CN¥39.26
+46.8%
12.4%CN¥47.45CN¥35.20n/a4
Aug ’24CN¥27.71
CN¥40.91
+47.6%
10.2%CN¥46.22CN¥36.00n/a3
Jul ’24CN¥27.38
CN¥45.24
+65.2%
7.8%CN¥49.00CN¥40.50CN¥13.703
Jun ’24CN¥29.56
CN¥45.24
+53.0%
7.8%CN¥49.00CN¥40.50CN¥15.093
May ’24CN¥32.06
CN¥43.36
+35.2%
6.6%CN¥46.22CN¥40.50CN¥16.122
Mar ’24CN¥39.14
CN¥50.46
+28.9%
0.08%CN¥50.51CN¥50.42CN¥20.462
Feb ’24CN¥44.44
CN¥50.46
+13.6%
0.08%CN¥50.51CN¥50.42CN¥18.312
Jan ’24CN¥42.43
CN¥50.46
+18.9%
0.08%CN¥50.51CN¥50.42CN¥24.212
Dec ’23CN¥40.22
CN¥50.46
+25.5%
0.08%CN¥50.51CN¥50.42CN¥28.132
Nov ’23CN¥37.78
CN¥59.78
+58.2%
22.0%CN¥78.40CN¥50.42CN¥28.533
Oct ’23CN¥39.18
CN¥59.78
+52.6%
22.0%CN¥78.40CN¥50.42CN¥28.983
Sep ’23CN¥41.38
CN¥59.78
+44.5%
22.0%CN¥78.40CN¥50.42CN¥26.753
Aug ’23CN¥47.30
CN¥63.18
+33.6%
17.1%CN¥78.40CN¥54.45CN¥27.713
Jul ’23CN¥50.27
CN¥63.18
+25.7%
17.1%CN¥78.40CN¥54.45CN¥27.383

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.